Moderna stock tanks on COVID vaccine delivery slowdown
Due to the delays and prioritization of low-income countries, Moderna anticipates fiscal year 2021 product sales between $15B and $18B, down from previous guidance of $20 billion.
via FOX BUSINESS NEWS Markets
https://ift.tt/3k6fSAK